Edgewise Therapeutics, Inc. (EWTX) Dividend History

Company News

• Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

  Edgewise Therapeutics' (EWTX) share price surged 50% in a single session due to positive results from early trials of its novel treatment for obstructive hypertrophic cardiomyopathy, a leading cause of sudden cardiac-related death in young people. The company's pipeline and strong financial position also contribute to the positive sentiment.

  Benzinga
• Why Edgewise Therapeutics Stock Is Up 50% on Thursday

  Edgewise Therapeutics' cardiac drug EDG-7500 shows promise in clinical trials for treating obstructive hypertrophic cardiomyopathy, a condition marked by thickening of the left heart ventricle wall. The drug was well-tolerated and did not lead to lowered left ventricular ejection fraction levels, a common issue with other cardiac drugs. However, any potential commercialization is still years away.

  The Motley Fool
• Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know

  The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  Zacks Investment Research
• Stocks To Watch: Spotlight On Tesla, Nio, Walgreens And Constellation Brands

  Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week

  Seeking Alpha

  Featured Companies: BLNK CAG CAT CENN KALA LW MSTR MULN SLP WBA